BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Genetown

  Gemini Will Cut 20% of Staff, Pivot All Resources to Geographic Atrophy

  The company announced that they are reducing its employee headcount and ceasing some of its research programs to focus on its geographic atrophy (GA) trial.

  October 6, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Takeda Pauses Narcolepsy Studies, Forges $1.1 Billion Gene Therapy Deal

  A safety concern has forced Takeda Pharmaceutical to suspend the dosing of patients in two Phase II studies of an experimental treatment for narcolepsy.

  October 6, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Global Roundup: BICO Group Acquires QInstruments and More

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  October 6, 2021

   · 

  6 min read

   · 

  Alex Keown
• 

  Deals

  Boston Scientific Bets $1.75 Billion on Baylis Medical’s Heart Portfolio

  The deal, which includes an upfront payment of $1.75 billion, enables Boston Scientific to expand its electrophysiology and structural heart product portfolio.

  October 6, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  Holmes Legal Team Attempts to Spread Blame to Former Theranos Lab Director

  Attorneys for Holmes have speculated that the lab failures at Theranos are the fault of Rosendorf and not Holmes herself.

  October 6, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Money on the Move: September 29 – October 5

  These life sciences companies scored enough capital this week for pumpkin spice and everything nice, and to propel their candidates in the clinic. Here’s a look.

  October 6, 2021

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Deals

  Pfizer and Voyager Launch $630 Million Gene Therapy Technology Pact

  Voyager Therapeutics entered a deal with Pfizer that allows Pfizer to exercise options to license novel capsids created by Voyager’s RNA-driven TRACER screening technology.

  October 6, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Merck’s Davis Looking to Diversify in Preparation for Keytruda Patent Cliff

  Newly appointed CEO Rob Davis must find a way to balance Merck’s portfolio before investors get (even more) antsy. And he is looking to be aggressive.

  October 6, 2021

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Retrotope Drug Improves Survival in Ultra-Rare Genetic Childhood Disease

  Retrotope cited data from its Phase II/III trial of RT001 in patients with infantile neuroaxonal dystrophy and reported on a natural history study of INAD patients’ disease onset and progression.

  October 6, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  Moderna Seeks to Shore Up Patent Protection on COVID-19 Vaccine

  Moderna seeks to invalidate two patents of Arbutus Biopharma Corp. The company hopes to appeal a preemptive challenge to the patents upheld by the U.S. Patent Trial and Appeals Board.

  October 6, 2021

   · 

  2 min read

   · 

  Alex Keown